Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Volumetric time series of false-colored GFP-histones in a live nematode embryo from the four-cell stage up to hatching. Wu et al. present diSPIM, a four-dimensional imaging method with isotropic resolution and minimal photobleaching (p 1032). Credit: Marina Spence, based on images from Yicong Wu and Hari Shroff.
The 2009 H1N1 pandemic showed that the egg-based technology used to produce the bulk of flu vaccine is not nimble enough to protect during a pandemic. Charles Schmidt reports on progress in synthetic and recombinant technologies that may provide an answer.
New technology has transformed human genetics. It now provides perhaps the single best opportunity to innovate and improve clinical success rates in drug development.
Too few precompetitive consortia are being formed to mitigate lost opportunities and deliver on other potential mutual gains for public and private stakeholders in drug development.
A study assesses Chinese scientists' knowledge of patents and the relationship between scientists' patent-using behaviors and their organizations' mandates.
Pools of cell lines carrying a variety of known mutations are used to validate the performance of a cancer diagnostic test based on next-generation sequencing.
RNA sequencing of 465 human lymphoblastoid cell lines across seven European laboratories shows the feasibility of transcriptome sequencing for population-wide and cross-biobank studies.
Clinical tests that rely on next-generation sequencing to evaluate large numbers of cancer genes can be validated using pooled cell lines with known mutations.
The problem of toxic intermediates in engineered metabolic pathways is mitigated by dynamic gene-expression regulation using stress-responsive promoters.